Tasquinimod + cabazitaxel in heavily pre-treated men with mCRPC

According to media information from Active Biotech this morning, the company has initiated an early stage, combination therapy trial (the so-called CATCH trial) of their investigational agent tasquinimod + cabazitaxel (Jevtana®) for the treatment of men with heavily pre-treated, metastatic, castration-resistant prostate cancer (mCRPC).

The media release from Active Biotech says that this study is a Phase I trial that will enroll just 30 patients with mCRPC. All eligible patients must be refractory to standard forms of chemotherapy. Additional information about this trial is available on the ClinicalTrials.gov web site. The trial is being conducted exclusively at the Duke Cancer Institute in Durham, North Carolina.

The primary objective for this trial is to identify an appropriate dose of tasquinimod that can be used in combination with cabazitaxel  in patients with this highly advanced form of prostate cancer. However, efficacy of the drug combination will also be assessed based on measurements of progression-free and overall survival.

The randomized, double-blind, placebo-controlled, Phase III study of tasquinimod in men with mCRPC (which we have previously discussed at some length) continues to enroll patients.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: